- Home
- NUVB vs CHI Comparison
NUVB vs CHI Comparison
Compare NUVB & CHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- CHI
- Stock Information
- Founded
- NUVB 2018
- CHI 2002
- Country
- NUVB United States
- CHI United States
- Employees
- NUVB N/A
- CHI N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- CHI Investment Managers
- Sector
- NUVB Health Care
- CHI Finance
- Exchange
- NUVB Nasdaq
- CHI Nasdaq
- Market Cap
- NUVB 679.9M
- CHI 696.7M
- IPO Year
- NUVB N/A
- CHI N/A
- Fundamental
- Price
- NUVB $2.12
- CHI $10.09
- Analyst Decision
- NUVB Strong Buy
- CHI
- Analyst Count
- NUVB 5
- CHI 0
- Target Price
- NUVB $8.20
- CHI N/A
- AVG Volume (30 Days)
- NUVB 4.2M
- CHI 186.2K
- Earning Date
- NUVB 05-07-2025
- CHI 01-01-0001
- Dividend Yield
- NUVB N/A
- CHI 9.90%
- EPS Growth
- NUVB N/A
- CHI N/A
- EPS
- NUVB N/A
- CHI N/A
- Revenue
- NUVB $10,957,000.00
- CHI N/A
- Revenue This Year
- NUVB $95.27
- CHI N/A
- Revenue Next Year
- NUVB $345.44
- CHI N/A
- P/E Ratio
- NUVB N/A
- CHI N/A
- Revenue Growth
- NUVB N/A
- CHI N/A
- 52 Week Low
- NUVB $1.54
- CHI $9.70
- 52 Week High
- NUVB $3.97
- CHI $11.61
- Technical
- Relative Strength Index (RSI)
- NUVB 47.71
- CHI 48.08
- Support Level
- NUVB $2.14
- CHI $10.11
- Resistance Level
- NUVB $2.42
- CHI $10.30
- Average True Range (ATR)
- NUVB 0.16
- CHI 0.14
- MACD
- NUVB -0.01
- CHI -0.04
- Stochastic Oscillator
- NUVB 27.71
- CHI 8.51
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.